-
Ethical Science News
-
Dec 13, 2022
New Analysis Supports Waiving Carcinogenicity Studies for Drugs; Reducing and Replacing Animal Use When Conducted
By analyzing publicly-available FDA reviews of recent new drug applications, researchers from the Physicians Committee confirmed that long-term carcinogenicity studies can often be waived based on what is already known about drugs without compromising patient safety; when they are conducted, implementing international recommendations on short-term and exposure studies, as well as controls, would further reduce animal use.